Dr Magnus Nicolson Mba Frsm Frsc Email & Phone Number

Motherwell, North Lanarkshire, Gb

Invizius Ltd is developing Second Generation Complement Therapeutics to reduce complement activation during CRRT, Haemodialysis, Peritoneal Dialysis, CPB and other applicable device and therapeutic applications. Complement activation is a driver of renal tubule cell damage, micro and cardiovascular damage as well as a driver of fibrosis and cell transformation. The lead product H-Guard is designed for Acute Haemodialysis applications.

Motherwell, North Lanarkshire, Gb

Oban, Argyll, Gb

SAMS are based in the European Marine Science Park at Dunstaffnage on the West Coast of Scotland. SAMS hosts the largest Algal collection in the world and are recognised leaders in global seaweed cultivation. Other projects I am involved in include CRISPR cas enhancement of Omega 3 production in algae and marine worm applications.

Glasgow, Gb

ILCT uses hybrid interferon alpha to modulate the Innate Immune System in a number of indications: Viral, Oncology, Dermatology and others.

Fixed Phage spun out of Strathclyde University in 2011 with patents covering the stabilisation of bacteriophages onto a variety of surfaces using corona discharge.

General & Project Management in Germany and UK, Facility Design, Refinery Design, Omega 3, Continuous Manufacturing, Cell Therapy and ATMP's . Technology areas: cGMP manufacturing, Stem Cells, Immunology Gene Therapy, Oncology and Drug Delivery.

Ludwigshafen, De

General management responsibility for all activities and staff at the BASF Pharma facility on Lewis as well as for large scale SMB expansion project for API production. Project managed design and build of new Omega 3 manufacturing facility in under 14 months and recruitment of key staff to move company forward at new scale. All regulatory agency audits passed and now providing high quality API lipid products to multiple customers globally.

A number of projects in personalised cellular therapy, biobanking, spinal injury and continued consultancy work on the siRNA Ryboquin project I started when CEO of EctoPharma Ltd.

Umbilical Cord Banking under Human Tissue Authority License

Private Speciality Pharmaceutical and Medical Device Company focusing on parasitology and moving into cancer therapy.

A drug delivery company based on hydrogel technology and exporting products to over 40 countries sold through distributors like Forest and Ferring. Research focus on obstetrics and autoimmune disease as well as successfully developing biodegradable polymers.

AMEX listed Biotechnology company developing biopharmaceutical products in the area of cancer and infectious diseases as well as platform transgenic technology.

Master'S Degree, Mba

Doctor Of Philosophy - Phd, Immunology